Abstracts tagged "plasma cells and signal transduction"

Abstract Number: 1053 • 2015 ACR/ARHP Annual Meeting
Phosphatidylinositol-3-Kinase Delta Pathway a Novel Therapeutic Target for Sjogren’s Syndrome
Saba Nayar¹, Joana Campos¹, Christopher Buckley¹, Rodger Allen², W.A. Fahy², Andrew Payne² and Francesca Barone¹, ¹University of Birmingham, Rheumatology Research Group, Birmingham, United Kingdom, ²UCB Pharma, Slough, United Kingdom
Background/Purpose: Sjögren’s syndrome (SS) is a chronic autoimmune disease characterized by B cell hyper-activation and exocrine gland infiltration that results in loss of glandular function,…
Abstract Number: 920 • 2013 ACR/ARHP Annual Meeting
Fms-Like Tyrosine Kinase 3 Signaling Is Essential For Differentiation Of Antigen Specific Plasma Cells During Experimental Arthritis
Mattias Svensson¹, Kersti Månsson¹, Karin Andersson¹, Mats Bemark², Mikael Brisslert¹ and Maria Bokarewa¹, ¹Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ²Microbiology and Immunology, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Signaling through the tyrosine kinase receptor Flt3 plays an important role in early B-cell development. Mice lacking either Flt3 or its ligand (Flt3L) have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].